[1] 张鑫宇, 刘皈阳, 祝晓光, 等. 非小细胞肺癌EGFR突变的检测方法[J]. 中国肺癌杂志, 2011, 14(3):297-302.
[2] 安娟, 汤传昊, 王娜, 等. MALDITOF质谱筛查NSCLC患者血清特异性多肽的探索性研究[J]. 中国肺癌杂志, 2013, 16(5): 233-239.
[3] 李永文, 刘红雨, 李颖, 等. 实时荧光定量PCR和测序法检测非小细胞肺癌EGFR基因突变的比较[J]. 中国肺癌杂志, 2009, 12(12):1255-1259.
[4] Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with nonsmallcell lung cancer[J]. J Clin Oncol, 2012, 30(4):433-440.
[5] Costa DB, Kobayashi S, Tenen DG, et al. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFRmutant nonsmall cell lung cancers[J]. Lung Cancer, 2007, 58(1):95-103.
[6] Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with nonsmall cell lung cancer and acquired resistance to gefitinib[J]. Clin Cancer Res, 2006, 12(19):5764-5769.
[7] 杨拴盈, 田应选, 南岩东, 等. 应用液体芯片飞行时间质谱技术筛选血清中肺癌标志蛋白[J]. 西安交通大学学报(医学版), 2011, 32(1):17-11.
[8] 陈晓, 刘良, 周华, 等. 全身多发转移与无转移非小细胞肺癌患者血浆蛋白组学比较分析[J]. 中国现代医学杂志, 2013, 23(27):30-34.
[9] Brevet M, Johnson ML, Azzoli CG, et al. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors[J]. Lung Cancer, 2011, 73(1):96-102.
[10] Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages ⅢB to Ⅳ nonsmallcell lung cancer[J]. J Clin Oncol, 2009, 27(16):2653-2659.
[11] 秦楚, 王朝霞. 非小细胞肺癌个体化治疗研究进展[J]. 中华临床医师杂志(电子版), 2013, 7(21):9681-9686.
[12] 刘丽华, 孟君, 张璁, 等. 运用MALDITOF MS方法建立食管癌患者血清蛋白指纹图谱诊断模型[J]. 肿瘤防治研究, 2012, 39(2):169-172.
[13] Wu X, Liang W, Hou X, et al. Serum proteomic study on EGFRTKIs target treatment for patients with NSCLC[J]. Onco Targets Ther, 2013, 6:1481-1491.
[14] 赵实诚, 许洋. 蛋白质指纹技术在临床医学的应用与研究进展[J]. 中华检验医学杂志, 2004, 27(10):706-709.
[15] 刘丹, 刘伦旭, 袁泉, 等. 运用激光解析电离飞行时间质谱技术检测肺腺癌的血清蛋白表达[J]. 四川大学学报·医学版, 2010, 41(3):498-500.
[16] Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumor subsets in nonsmall cell lung cancer[J]. Lancet, 2003, 362(9382):433-439.
[17] Lazzari C, Spreafico A, Bachi A, et al. Changes in plasma massspectral profile in course of treatment of nonsmall cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors[J]. J Thorac Oncol, 2012, 7(1):40-48.
[18] Chung CH, Seeley EH, Roder H, et al. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(2):358-365.
[19] 郭帅, 李智立. 质谱成像及其在生物医学领域的应用[J]. 生物物理学报, 2011, 27(12):1008-1018.
[20] 杨帆, 原剑, 郑俊杰, 等. MALDITOF生物质谱成像技术的进展[J]. 分析仪器, 2010, 3:1-8.
[21] Shimma S, Sugiura Y, Hayasaka T, et al. MALDIbased imaging mass spectrometry revealed abnormal distribution of phospholipids in colon cancer liver metastasis[J]. J Chromatogr B Analyt Biomed Life Sci, 2007, 855(1):98-103.
[22] Altelaar AF, Taban IM, McDonnell LA, et al. Highresolution MALDI imaging mass spectrometry allows localization of peptide distributions at cellular length scales in pituitary tissue sections[J]. Int J Mass Spectrom, 2007, 260(2-3):203-211.
[23] 张莹, 陈岚, 陆豪杰, 等. MALDI质谱成像技术在非小细胞肺癌中的应用研究[J]. 质谱学报, 2007, 28(4):209-213. |